Asieris'Bladder Cancer Diagnostic Drug Hexvix® Completed Dosing of First Patient in Real-World Clinical Study

SHANGHAI,Dec. 12,2022 -- Asieris Pharmaceuticals (688176),a global biopharma company specializing in discovering,developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases,announced that Hexvix®,a drug used for bladder cancer diagnosis,completed dosing for first patient in its real-world clinical study at Hainan General Hospital Lecheng Branch.

Hexvix® has been approved in the United States and many European countries. The combined use of Hexvix® and blue light cystoscopy (BLC) for the management of non-muscle invasive bladder cancer (NMIBC) has been included in the global expert consensus guidelines as well as the Chinese Urological Association Guideline.

In January 2021,Asieris Pharmaceuticals entered into a license agreement with Photocure ASA (Photocure,OSE:PHO),a bladder cancer specialty company based in Oslo,Norway,and obtained the exclusive registration and commercialization rights of Hexvix® in mainland China and Taiwan.

"Thanks to the policies introduced by the Hainan Provincial Government and the Bo'ao Lecheng Pilot Zone of International Medical Tourism,we successfully completed dosing of Hexvix® for the first patient in our real-world clinical study. By taking advantage of the beneficial policy associated with real-world studies in Hainan,we hope to accelerate the approval of the innovative product Hexvix® in China to meet the growing medical needs of bladder cancer patients," said Dr. Zhuang Chengfeng,Chief Operating Officer of Asieris Pharmaceuticals.

About Asieris

Asieris Pharmaceuticals(688176.SH),founded in March 2010,is a global biopharma company specializing in discovering,developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases. We strive to improve human health and help people live a more dignified life. We aim to become a global pharma leader that integrates R&D,manufacturing and commercialization in our areas of focus,as we provide best-in-class integrated diagnosis and treatment solutions for patients in China and worldwide.

The company has been developing its proprietary R&D platform and core technologies,exploring new mechanisms of action,and efficiently screening and evaluating drug candidates. With a well-established in-house R&D system and expertise in global drug development,Asieris is committed to launching first-in-class drugs and other innovative products to address huge unmet needs in its areas of focus.

Asieris is also enhancing its pipeline for genitourinary diseases via proprietary R&D and strategic partnerships,while closely following cutting-edge technologies and therapeutics. The company strives to discover and identify unmet clinical needs,and adopts a forward-looking approach in product planning and life-cycle management. We aim to establish an outstanding portfolio that covers diagnosis and treatment in a bid to benefit more patients in China and globally.

View original content:https://www.prnewswire.com/news-releases/asierisbladder-cancer-diagnostic-drug-hexvix-completed-dosing-of-first-patient-in-real-world-clinical-study-301700263.html